Dynavax Reports Phase 1/2 Data For Shingles Vaccine Z-1018, Begins Head-To-Head Trial vs. Shingrix In Adults 70+

Author: Benzinga Newsdesk | October 21, 2025 03:23pm

• Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile
• Newly presented data outline robust polyfunctional CD4+ T-cell responses in Z-1018 arms
• Company initiates Part 2 of Phase 1/2 head-to-head versus Shingrix in adults 70 years and older

EMERYVILLE, Calif., Oct. 21, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today presented positive topline data from Part 1 of its randomized, observer-blinded, active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, in a late-breaker session at IDWeek 2025. Dynavax also today announced it has initiated Part 2 of the trial evaluating Z-1018 head-to-head versus Shingrix® in older adults.

Posted In: DVAX